5

10

15

20

25

## Claims

- 1. A method for routine determination of IC<sub>50</sub> or EC<sub>50</sub> values for compounds via biological assay at a single concentration, which comprises:
- a) Identifying a biological assay capable of producing a percent effect for a compound tested for activity against a target at a known concentration;
- b) Performing the assay on an initial collection of at least 10 compounds, and at least 1 commercially available compound to be used as positive control, each assayed at a set of 3 to 10 or more concentrations, measuring a percent effect at each concentration for each compound;
- c) Determining an  $IC_{50}$  or  $EC_{50}$  for each of these initial compounds by fitting a mathematical dose response curve to the data for each compound, using a computer, and standard linear or nonlinear regression techniques;
- d) Using the resultant data from these initial compounds to fit a mathematical relationship between the  $IC_{50}$  or  $EC_{50}$  values and the percent inhibition values at a single fixed concentration X,
- e) Using a computer, and standard linear or nonlinear regression techniques, developing an equation relating  $IC_{50}$  or  $EC_{50}$  to percent inhibition or percent response on all remaining and future test compounds, at the previously fixed single concentration X, and determining the  $IC_{50}$  or  $EC_{50}$  via the mathematical equation developed in step d).
- 2. The method of claim 1 wherein said mathematical dose response curve is the Hill function,

$$percent inhibition = \frac{100}{1 + \left(\frac{IC_{50}}{concentration}\right)^{h}}$$

- 3. The method of claim 1 wherein said mathematical relationship is  $IC_{50} = \exp\{a + b \cdot (\text{percent inhibition at concentration } X)\}$ .
  - 4. The method of claim 1 wherein said biological assay is an assay for drug-drug interactions related to the target cytochrome P450 (CYP).

5

10

- 5. The method of claim 4 wherein the target is selected from the group consisting of CYP2C9, CYP2D6, CYP3A4, CYP1A2, and CYP2C19.
  - 6. The method of claim 1 where the target is an enzyme.
  - 7. The method of claim 1 wherein the target is a receptor.
  - 8. The method of claim 1 wherein the target is a transporter.
- 9. The method of claim 1 wherein said biological assay relates to affinity for any target protein wherein modulation of activity is therapeutically desired.
- 10. The method of claim 1 wherein said biological assay relates to affinity for any nontherapeutic protein wherein modulation of said activity is undesirable.